Statin use and the risk of developing diabetes: a network meta‐analysis

@article{Thakker2016StatinUA,
  title={Statin use and the risk of developing diabetes: a network meta‐analysis},
  author={Divyesh Thakker and Sunita R. Nair and Amit Pagada and Vinayak Sudhir Jamdade and Anuradha Malik},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2016},
  volume={25},
  pages={1131 - 1149}
}
Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta‐analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices. 
View on Wiley
ncbi.nlm.nih.gov
69 Citations
Background Citations
12
Methods Citations
1
Results Citations
3

69 Citations

Citation Type

Citation Type

Statin users have an elevated risk of dysglycemia and new‐onset‐diabetes
TLDR
This work sought to understand the risk of dysglycemia and NOD for a cohort of individuals that reflect real‐world physician prescribing patterns and identify patients at risk of new‐onset‐diabetes development. Expand
Associations of statin use with glycaemic traits and incident type 2 diabetes
TLDR
This study aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes. Expand
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
TLDR
To evaluate the association of statins and co‐morbidities with new onset type 2 diabetes mellitus (T2DM) in patients 65 years and older, a large number of patients with T2DM are enrolled. Expand
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.
TLDR
Overall, NOD risk was higher in statin users than nonusers and the evidence of a diabetogenic effect by statins utilization was reinforced, confirming the need of a rigorous monitoring of patients taking statins, in particular pre-diabetic patients or patients presenting with established risk factors for diabetes. Expand
Statins and diabetes: focus on pitavastatin
TLDR
Particular attention is paid to the place of pitavastatin, due to its low diabetogenicity and minimal risk of drug interactions, as well as the need of taking into consideration the risk factors of diabetes and the preventive measures in patients receiving statin therapy. Expand
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient.
  • J. Lillo
  • Medicine
  • The Journal of family practice
  • 2021
TLDR
The nocebo effect is a common reason for perceived statin intolerance and several strategies are available that can enable continuation of statin therapy in patients who are truly statin-intolerant. Expand
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
TLDR
In this population at high risk for diabetes, the authors observed significantly higher rates of diabetes with statin therapy in all three treatment groups, and the effect of statins to increase diabetes risk appears to extend to populations at highrisk for diabetes. Expand
Statin use and safety concerns: an overview of the past, present, and the future
TLDR
The most common adverse effects of statins are described, available evidence is examined and the role of ethnicity, lipophilicity and other biological factors that could mediate and/or influence the relationship are highlighted. Expand
Association between statin treatment and new-onset diabetes mellitus: a population based case–control study
  • Dong-Won Kim, Do-Hoon Kim, +8 authors Yong-Gyu Park
  • Medicine
  • Diabetology & Metabolic Syndrome
  • 2019
TLDR
The risk of NODM was not associated with an increase in the cumulative duration of statin use or with non-recent use, and only recent short-term use of cholesterol-lowering statin was associated with a increased risk ofNODM. Expand
Diabetes Caused by Statin Use: A Review
TLDR
Many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
TLDR
Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship ofstatin therapy to incident diabetes remains uncertain and future statin trials should be designed to formally address this issue. Expand
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
TLDR
A meta-analysis of published and unpublished data found that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Expand
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.
TLDR
Different types and doses of statins show different potential to increase the incidence of DM. Expand
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
TLDR
A meta-analysis and indirect comparisons employed to identify differing risk effects across statins found that atorvastatin significantly elevated AST levels compared to pravastatin and simvASTatin significantly increased CK levels when compared to rosuvastsatin. Expand
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
TLDR
Statin therapies offer clear benefits across broad populations, and as generic formulations become more available efforts to expand access should be a priority. Expand
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
TLDR
In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dosestatin therapy. Expand
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
TLDR
As a class, adverse events associated with statin therapy are not common but do result in a higher odds of diabetes mellitus and among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins. Expand
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
TLDR
Treatment with a low dose of pravastatin reduces the risk of coronary heart disease in Japan by much the same amount as higher doses have shown in Europe and the USA. Expand
Management of cardiovascular risk: the importance of meeting lipid targets.
TLDR
An update on recent guidelines, risk algorithms, and trials related to the prevention and treatment of coronary artery disease is provided. Expand
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.
TLDR
Pitavastatin did not adversely affect glucose metabolism or diabetes development compared with placebo or other statins, and potential publication bias may occur for NOD. Expand
...
1
2
3
4
5
...